The key to unlocking CARs
Nature Biotechnology 35, 889 (2017).
doi:10.1038/nbt.3993
Although Kymriah's approval represents a landmark for chimeric antigen receptor T-cell (CAR-T) therapy in B-cell malignancies, solid tumors remain a formidable challenge.
Source: Nature Biotechnology - Category: Biotechnology Tags: Editorial Source Type: research
More News: Biotechnology | Cancer & Oncology